- Home
- FOUR vs FOLD Comparison
FOUR vs FOLD Comparison
Compare FOUR & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FOUR | FOLD |
|---|---|---|
| Founded | 1999 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.4B |
| IPO Year | 2020 | 2007 |
Fundamental Metrics
Financial Performance| Metric | FOUR | FOLD |
|---|---|---|
| Price | $66.74 | $14.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 9 |
| Target Price | ★ $99.32 | $27.56 |
| AVG Volume (30 Days) | 1.6M | ★ 20.8M |
| Earning Date | 02-17-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.66 | N/A |
| EPS | ★ 2.15 | N/A |
| Revenue | ★ $3,878,400,000.00 | $598,704,000.00 |
| Revenue This Year | $28.69 | $21.49 |
| Revenue Next Year | $24.52 | $18.42 |
| P/E Ratio | $30.76 | ★ N/A |
| Revenue Growth | ★ 23.16 | 21.28 |
| 52 Week Low | $61.23 | $5.51 |
| 52 Week High | $127.50 | $14.36 |
Technical Indicators
Market Signals| Indicator | FOUR | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 51.64 | 90.18 |
| Support Level | $61.42 | $14.26 |
| Resistance Level | $66.25 | $14.35 |
| Average True Range (ATR) | 2.14 | 0.06 |
| MACD | 0.44 | -0.05 |
| Stochastic Oscillator | 91.51 | 67.50 |
Price Performance
Historical ComparisonAbout FOUR Shift4 Payments Inc.
Shift4 Payments Inc is provider of integrated payment processing and technology solutions. The company offers software providers a single integration to an end-to-end payments offering, a powerful gateway and a robust suite of technology solutions (including cloud enablement, business intelligence, analytics, and mobile) to enhance the value of their software suites and simplify payment acceptance. The company derives maximum revenue from United States.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.